New drug duo aims to help lung fibrosis patients breathe easier
NCT ID NCT07570888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding nerandomilast to the standard drug mycophenolate is safe and tolerable for people with pulmonary fibrosis (lung scarring). About 120 adults with various types of lung fibrosis will take the combination for 4 months. The main goal is to see how many can stay on the new drug without stopping due to side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can an inhaled powder stop lung scarring? a safety trial begins
- Repairing lungs from within: stem cells harvested from Patients' own airways tested for scarring disease
- AI could uncover hidden lung disease in routine chest X-Rays